載入...

Rescue of tolerant CD8(+) T cells during cancer immunotherapy with IL2:antibody complexes

Interleukin-2 (IL2) was among the earliest reagents used for cancer immunotherapy due to its ability to support the survival and function of tumor-reactive T cells. However, treatment with IL2 is accompanied by off-target toxicity and low response rates in patients. In mouse models, these issues are...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Immunol Res
Main Authors: Klevorn, Lauryn E., Berrien-Elliott, Melissa M., Yuan, Jinyun, Kuehm, Lindsey M., Felock, Gregory D., Crowe, Sean A., Teague, Ryan M.
格式: Artigo
語言:Inglês
出版: 2016
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5135645/
https://ncbi.nlm.nih.gov/pubmed/27803062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0159
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!